NCT01722539 (PIP-IPT) is a Phase 3 clinical trial of Sulfadoxine-pyrimethamine in Healthy, sponsored by Universiteit Antwerpen.

Who is sponsoring NCT01722539?

NCT01722539 is sponsored by Universiteit Antwerpen.

What drugs are being tested in NCT01722539?

Interventions in NCT01722539: Sulfadoxine-pyrimethamine, Piperaquine, Albendazole, Praziquantel.

Is NCT01722539 still recruiting?

NCT01722539 is currently completed. Last updated 3 February 2014.

Last reviewed 2014-02-03 · How we verify

NCT01722539: PIP-IPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial

Completed Phase 3 Last updated 3 February 2014

What this trial tests

Phase 3 trial testing Sulfadoxine-pyrimethamine in Healthy in 616 participants. Completed in 1 November 2013.

Timeline

1 November 2012

Primary endpoint
1 November 2013

1 November 2013

Quick facts

Lead sponsor	Universiteit Antwerpen
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	616
Start date	1 November 2012
Primary completion	1 November 2013
Estimated completion	1 November 2013
Sites	1 location across Republic of the Congo

Drugs / interventions tested

Sulfadoxine-pyrimethamine
Piperaquine — full drug profile →
Albendazole (ALBENDAZOLE) — full drug profile →
Praziquantel — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Universiteit Antwerpen — full company profile →

Who can join

Adults 5 to 14, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hemoglobin change
Time frame: Month 0-Month 12
Change in mean Hb concentration at month 12 of follow-up and anaemia prevalence one year after initial preventive treatment;

Sponsor's own description

Considering the facts that: (i) IPT of malaria provides substantial protection against anaemia and malaria in school children (ii); SP resistance has no significant impact on the prophylactic efficacy (iii) SP-PQ is safe and as efficacious as SP: the investigators hypothesize that antimalarial IPT with SP and SP-PQ will improve haemoglobin concentration, reduce anaemia prevalence, malaria incidence and parasitaemia, and improve malnutrition and school performance in school-aged children of Congo.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Malaria, schistosomiasis and soil transmitted helminth burden and their correlation with anemia in children attending primary schools in Kinshasa, Democratic Republic of Congo.
Matangila JR, Doua JY, Linsuke S, Madinga J, et al · · 2014 · cited 39× · PMID 25372029 · DOI 10.1371/journal.pone.0110789
Intermittent preventive treatment: efficacy and safety of sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine plus piperaquine regimens in schoolchildren of the Democratic Republic of Congo: a study protocol for a randomized controlled trial.
Doua JY, Matangila J, Lutumba P, Van Geertruyden JP. · · 2013 · cited 10× · PMID 24063608 · DOI 10.1186/1745-6215-14-311
Poster Sessions
· 2015

Verify or expand the search:

Other trials of Sulfadoxine-pyrimethamine

Trials testing the same drug.

NCT03009526 — Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi · Phase 3 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Universiteit Antwerpen trials

Trials by the same sponsor.

NCT07407569 — Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After H · Phase 2 · recruiting
NCT07355101 — Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD · NA · active not recruiting
NCT06962579 — The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
NCT06999473 — Assessment and Treat Neglect Patients With a VR Application · NA · not yet recruiting
NCT07161531 — Test-retest Reliability of sEMG to Measure Fatigue in Adolescents · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01722539 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universiteit Antwerpen
Last refreshed: 3 February 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01722539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing